Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI

This study has been completed.

Sponsor:

Collaborators:

The Cleveland Clinic

Centocor, Inc.

Eli Lilly and Company

Information provided by (Responsible Party):

Harmony R. Reynolds, New York University School of Medicine

ClinicalTrials.gov Identifier:

NCT00245648

First received: October 27, 2005

Last updated: October 3, 2012

Last verified: October 2012

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	October 2007
Primary Completion Date:	October 2007 (Final data collection date for primary outcome measure)

No publications provided by New York University School of Medicine

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Reynolds HR, Farkouh ME, Lincoff AM, Hsu A, Swahn E, Sadowski ZP, White JA, Topol EJ, Hochman JS; GUSTO V Investigators. Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V. Arch Intern Med. 2007 Oct 22;167(19):2054-60.

To Top